3 results match your criteria: "USA Stanford Cardiovascular Institute[Affiliation]"
Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension.
Cardiovasc Res
July 2015
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Department of Experimental Medical Science, Lund University, Lund, Sweden.
Aims: Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation.
View Article and Find Full Text PDFHow does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience.
BMJ Open
June 2014
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA Stanford Cardiovascular Institute, Stanford Cardiovascular Medicine, Stanford, California, USA.
Objectives: It is unclear if morphology impacts on diastole in hypertrophic cardiomyopathy (HCM). We sought to determine the relationship between various parameters of diastolic function and morphology in a large HCM cohort.
Setting: Tertiary referral centre from Stanford, California, USA.
Clinical and socioeconomic factors associated with unrecognized peripheral artery disease.
Vasc Med
August 2014
Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA Stanford Cardiovascular Institute, Stanford, CA, USA
Peripheral artery disease (PAD) is a highly prevalent condition that frequently goes undetected and untreated. Socioeconomic factors associated with unrecognized PAD are not known. The ankle-brachial index (ABI) was calculated in 1656 study participants undergoing non-emergent coronary angiography with PAD defined as an ABI <0.
View Article and Find Full Text PDF